14 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow Zollinger-Ellison Syndrome: new trials by email Literature Review of Zollinger-Ellison Syndrome trials Research Report on Zollinger-Ellison Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg - Gastric Ulcer (GU), Duodenal Ulcer (DU) | Phase 3 | Completed | AstraZeneca | 55 | 2014-06-01 | 2017-01-19 |
| Nexium Capsules Clinical Experience Investigation Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome | Completed | AstraZeneca | 3691 | 2011-09-01 | 2014-04-16 | |
| YF476 and Type II Gastric Carcinoids YF476 - Zollinger-Ellison Syndrome | Phase 2 | Terminated | Trio Medicines Ltd. | 3 | 2011-04-11 | 2021-01-29 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole - Healthy | Phase 1 | Completed | Takeda | 160 | 2009-12-01 | 2012-02-03 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-03-01 | 2020-04-03 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Esomeprazole magnesium (Nexium) - Zollinger-Ellison Syndrome | Phase 3 | Completed | AstraZeneca | 25 | 2003-11-01 | 2010-11-19 |
| Treatment of Zollinger-Ellison Syndrome With Prevacid Lansoprazole (Prevacid) - Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia | Phase 4 | Completed | Charles Mel Wilcox, MD | 72 | 2003-03-01 | 2012-10-30 |
| Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Zollinger Ellison Syndrome | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 273 | 1991-10-29 | 2026-09-28 | |
| Treatment of Zollinger-Ellison Syndrome Zollinger Ellison Syndrome | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1989-01-27 | 2017-07-02 | ||
| Evaluating Patients With Abnormal Levels of Gastric Acid Achlorhydria, Gastrinoma | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1989-01-01 | 2008-03-05 | ||
| Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Interferon - Islet Cell Adenoma, Zollinger Ellison Syndrome | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 50 | 1988-10-25 | 2017-07-02 |
| The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Pantoprazole, Omeprazole - Gastrinoma, Zollinger Ellison Syndrome | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1983-02-03 | 2017-07-02 | |
| Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin - Islet Cell Adenoma, Neoplasm Metastasis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 999 | 1978-09-01 | 2008-03-04 |
Gastrinoma (4) · Somatostatinoma (4) · Carcinoma, Medullary (3) · Esophagitis, Peptic (3) · Glucagonoma (3) · Insulinoma (3) · Stomach Ulcer (3) · Adenoma, Islet Cell (2) · Carcinoid Tumor (2) · Carcinoma, Merkel Cell (2) · Duodenal Ulcer (2) · Multiple Endocrine Neoplasia Type 1 (2) · Neuroendocrine Tumors (2) · Pheochromocytoma (2)
Digestive System Diseases (16) · Digestive System Neoplasms (16) · Duodenal Diseases (16) · Gastrointestinal Diseases (16) · Gastrointestinal Neoplasms (16) · Intestinal Diseases (16) · Neoplasms (16) · Paraneoplastic Endocrine Syndromes (16) · Paraneoplastic Syndromes (16) · Peptic Ulcer (16) · Stomach Diseases (16) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Neoplasms by Site (9) · Neoplasms by Histologic Type (8)
Capecitabine (2) · Esomeprazole (2) · Lansoprazole (2) · Omeprazole (2) · Temozolomide (2) · Acetates (1) · Clopidogrel (1) · Dexlansoprazole (1) · Doxorubicin (1) · Everolimus (1) · Fluorouracil (1) · Interferons (1) · Octreotide (1) · Pantoprazole (1) · Salts (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · AstraZeneca (3) · National Cancer Institute (NCI) (2) · Charles Mel Wilcox, MD (1) · Columbia University (1) · Takeda (1) · Trio Medicines Ltd. (1) · Vanderbilt-Ingram Cancer Center (1)
United States (11) · Japan (2) · France (1)
James Yao (2) · C. Mel Wilcox, M.D. (1) · Jordan Berlin, M.D. (1) · Paul E Oberstein, MD (1) · Robert T Jensen, M.D. (1) · Shigeru Yoshida, MD (1)
PMID 15645403, PMID 17767471, PMID 18507843, PMID 19581810, PMID 21073392, PMID 21193359, PMID 22464259, PMID 23333143, PMID 25900182, PMID 25956795
P30CA016672 (2), N01CM62202 (1), U01CA062461 (1), U01CA062490 (1)